DiaMedica Therapeutics Inc. (DMAC): Price and Financial Metrics


DiaMedica Therapeutics Inc. (DMAC)

Today's Latest Price: $9.31 USD

0.42 (4.72%)

Updated Jan 25 6:55pm

Add DMAC to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

DMAC Stock Price Chart Interactive Chart >

Price chart for DMAC

DMAC Price/Volume Stats

Current price $9.31 52-week high $10.88
Prev. close $8.89 52-week low $1.87
Day low $8.50 Volume 141,800
Day high $9.40 Avg. volume 184,127
50-day MA $7.32 Dividend yield N/A
200-day MA $5.48 Market Cap 174.46M

DiaMedica Therapeutics Inc. (DMAC) Company Bio

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Most Popular Stories View All

• Is General Motors the Next Tesla?

• How to Outperform the Stock Market in 2021

• 2 Chinese Stocks Rated Strong Buy: EHang and Daqo

• 3 Lesser-Known Cloud Stocks to Add to Your Portfolio

• Is Virgin Galactic a Buy After a New Space Stock ETF was announced?

View All Top Stories

DMAC Latest News Stream

Event/Time News Detail
Loading, please wait...
View All DMAC News

DMAC Latest Social Stream

Loading social stream, please wait...

View Full DMAC Social Stream

Latest DMAC News From Around the Web

Below are the latest news stories about DiaMedica Therapeutics Inc that investors may wish to consider to help them evaluate DMAC as an investment opportunity.

DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021. The recorded presentation will be available on the Investors section of the Company’s website at https://ir.diamedica.com/events-and-presentations beginning Monday, January

Business Wire | January 11, 2021

Here's Why We're Not At All Concerned With DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 9, 2021

DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company’s Phase 2 REDUX chronic kidney disease (CKD) study. The Company also announced that enrollment has reached 50% in the IgA Nephropathy and African Americans cohorts. DiaMedica’s Phase 2 REDUX (Latin for restore) study is a multi-center, open-label, investigation to assess the safety and effica

Business Wire | December 15, 2020

Is DMAC A Good Stock To Buy Now?

In this article we will take a look at whether hedge funds think DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | December 11, 2020

DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the Company submitted in October 2020 regarding the Company’s development plan for its product candidate, DM199, in the treatment of acute ischemic stroke (AIS). DiaMedica believes that the feedback received from the FDA provides a well-defined regulatory pathway and plans to immediately proceed with preparing

Business Wire | December 10, 2020

Read More 'DMAC' Stories Here

DMAC Price Returns

1-mo N/A
3-mo 124.88%
6-mo 57.80%
1-year 121.67%
3-year N/A
5-year N/A
YTD -8.19%
2020 109.07%
2019 66.67%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7134 seconds.